Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
Inhibikase Therapeutics, Inc. (IKT)
Company Research
Source: GlobeNewswire
-- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and 60 -- BOSTON and ATLANTA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Cardiopulmonary and Neurodegenerative disease through Abelson Tyrosine Kinase inhibition, today announced the closing of a private placement of approximately $110 Million from the issuance and sale of shares of the Company’s common stock and accompanying warrants with potential aggregate financing of up to approximately $275 Million upon the full cash exercise of the warrants issued in the private placement, before deducting placement agent fees and offering expenses. The financing will fund execution of the Phase 2b ‘702’ trial in Pulmonary Art
Show less
Read more
Impact Snapshot
Event Time:
IKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IKT alerts
High impacting Inhibikase Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IKT
News
- Inhibikase Therapeutics GAAP EPS of -$0.65 misses by $0.17 [Seeking Alpha]Seeking Alpha
- Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent ActivityGlobeNewswire
- Inhibikase Therapeutics, Inc. (NYSE: IKT) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $8.00 price target on the stock.MarketBeat
- Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension [Yahoo! Finance]Yahoo! Finance
- Inhibikase Therapeutics, Inc. (NYSE: IKT) had its price target lowered by analysts at HC Wainwright from $15.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
IKT
Earnings
- 11/14/24 - Miss
IKT
Sec Filings
- 11/18/24 - Form S-3
- 11/18/24 - Form DEF
- 11/14/24 - Form SC
- IKT's page on the SEC website